Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CV9103
- Development stage
- Phase 2
- Lead developer
- BioNTech
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
CV9103 is an investigational therapeutic cancer vaccine developed using self-adjuvanted messenger RNA (mRNA) technology (RNActive) by CureVac. It encodes full-length mRNAs for four antigens commonly overexpressed in prostate cancer cells—prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), and six-transmembrane epithelial antigen of the prostate 1 (STEAP1). The vaccine is designed to stimulate both T-cell and B-cell immune responses against these tumor-associated antigens, aiming to induce a broad and robust anti-tumor immunity. Clinical studies have shown that CV9103 is well tolerated with high immunogenicity in patients with advanced or metastatic castration-resistant prostate cancer. Its mechanism involves intradermal administration of the mRNA complexed with protamine to enhance immune activation[1][2][5][6].
- Other names
- mRNA-derived prostate cancer vaccine CV9103mRNA prostate cancer vaccine - CureVac
02
Targets
PSCA (Prostate stem cell antigen)PSA (Puromycin-sensitive aminopeptidase)PSMA (Prostate-specific membrane antigen)STEAP1 (Six-transmembrane epithelial antigen of prostate 1)
Beyond the preview
Go deeper on CV9103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CV9103.